The biotech stock that went to zero: a terrifying lesson in risk
This is a brutal but essential war story. An analyst slapped a $0 price target on drugmaker Sarepta after a third death was linked to its gene thera...
This is a brutal but essential war story. An analyst slapped a $0 price target on drugmaker Sarepta after a third death was linked to its gene thera...